MeMed COVID-19 Severity

3 Biomarkers + Machine Learning = MeMed COVID-19 Severity

A finalist for AACC’s 2021 Disruptive Technology Award, the MeMed COVID-19 Severity test builds on an extensive body of evidence supporting the role of viral-induced TRAIL and IP-10 and inflammatory CRP proteins in severe SARS-CoV-2 infection.1-3*

From a small serum sample, MeMed COVID-19 Severity computationally integrates the levels of these three host immune proteins into a simple score indicating the likelihood of patient deterioration.

To escalate or not to escalate level of care?

Some infections resolve quickly, others lead to severe immune dysregulation, respiratory failure and death. Distinguishing between the two is challenging.

1 in 5

Patients experience life threatening disease4




Over admission6


Average cost per non-ICU patient7

Conventional tests are important, but insufficient to aid in effective patient management

Uncertainty regarding results interpretation

Fail to alert prior to organ damage

Prolonged turnaround time

Inaccurate risk stratification

Unable to capture disease complexity

Interpreting results

0 20 40 80 100

0 ≤ score ≤ 20
Very low
likelihood of severe outcome

20 < score < 40
likelihood of severe outcome

40 ≤ score ≤ 80
likelihood of severe outcome

80 < score < 100
likelihood of severe outcome

MeMed COVID-19 Severity: Predictive & Actionable


  • Early indication of deterioration
  • Predictive of further disease progression vs. recovery


  • Ease of use: single serum sample per test
  • 15 minutes from sample to result
  • Easy to interpret results


* applying a score of 40 cutoff

Negative Predictive Value (NPV)*

* applying a score of 40 cutoff


** applying a score of 80 cutoff

Results reference: Independent validation study results, data not published yet.

MeMed COVID-19 Severity signature compares favorably with other biomarkers6

Comparison of area under ROC curve (AUC)

*MeMed COVID-19 Severity is CE-IVD and available in the EU and Israel. MeMed COVID-19 Severity is not cleared by the FDA for any indication, and is not available for sale in the US.


  1. Ivanisenko NV, Seyrek K, Kolchanov NA, Ivanisenko VA, Lavrik IN. The role of death domain proteins in host response upon SARS-CoV-2 infection: Modulation of programmed cell death and translational applications. Cell Death Dis. 2020 Oct 10;6(1):1-0.
  2. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Infect Dis. 2021 Jun 1;9(6):622-42.
  3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.
  4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-42.
  5. Kilaru AS, Lee K, Snider CK, Meisel ZF, Asch DA, Mitra N, et al. Return hospital admissions among 1419 COVID‐19 patients discharged from five US emergency departments. Acad Emerg Med. 2020 Oct;27(10):1039-42.
  6. Mastboim NS, Angel A, Shaham O, Ber TI, Navon R, Simon E, et al. An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome. medRxiv. 2021 Jan 1.
  7. Infographic: Covid-19 patients with high-risk conditions 3x more likely to need the ICU. Blue Cross Blue Shield. (n.d.). Retrieved March 15, 2022, from
Toggle content

Contact Us

7 Nahum Het St., Tirat Carmel
Park High-Tech North, 3508506, Israel
200 Brickstone Sq., Ste.106
Andover, MA 01810, USA